Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Stem cell transplantation for mantle cell lymphoma: if, when and how?

Bone Marrow Transplantation volume 36, pages 655–661 (2005)Cite this article

Summary:

Although the prognosis for mantle cell lymphoma (MCL) patients has improved in recent years, the outlook for those with advanced or recurrent disease remains poor. High-dose chemotherapy and autografting performed early in responding patients appears to be a method to extend progression-free survival (PFS) and overall survival (OS). The use of monoclonal antibody therapy added into the initial therapy and in the peritransplant period may improve on these results. Myeloablative allogeneic transplant appears to be a modality capable of providing curative therapy, but is plagued by a high treatment-related mortality, especially in older patients. Reduced-intensity conditioning allografting have fewer problems associated with the initial phase of transplant and hence may be preferred for those patients for whom an allograft is considered but have comorbid conditions or age issues that preclude a full allograft. Long-term results are lacking and the side effects associated with chronic GVHD may be as significant and debilitating. Trials designed to look at newly diagnosed patients with MCL examining the outcomes after planned autologous and allogeneic transplant as part of the initial management are needed to confirm the role of these various modalities in the overall therapy of this poor-outcome lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Frater JL, His E . Properties of the mantle cell and mantle cell lymphoma. Curr Opin Hematol 2002; 9: 56–60.

    Article  Google Scholar 

  2. Leonard JP, Schattner EJ, Coleman M . Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001; 13: 342–347.

    Article  CAS  Google Scholar 

  3. Jacobsen E, Freedman A . An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16: 106–113.

    Article  Google Scholar 

  4. Ganti AK, Bierman PJ, Lynch JC et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16: 618–624.

    Article  CAS  Google Scholar 

  5. Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1995; 8: 701–704.

    Article  Google Scholar 

  6. Stewart DA, Vose JM, Weisenburger DD et al. The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263–266.

    Article  CAS  Google Scholar 

  7. Milpied N, Gaillard F, Moreau P et al. High dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645–650.

    Article  CAS  Google Scholar 

  8. Freedman AS, Neuberg D, Gribben JG et al. High dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission. J Clin Oncol 1998; 16: 13–18.

    Article  CAS  Google Scholar 

  9. Dreger P, von Neuhoff N, Kuse R et al. Sequential high dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8: 401–403.

    Article  CAS  Google Scholar 

  10. Kroger N, Hoffknecht M, Dreger P et al. Long term disease free survival of patients with advanced mantle cell lymphoma following high dose chemotherapy. Bone Marrow Transplant 1998; 21: 55–57.

    Article  CAS  Google Scholar 

  11. Blay JY, Sebban C, Surbiguet C et al. High dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non Hodgkins lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21: 51–54.

    Article  CAS  Google Scholar 

  12. Vose JM, Bierman PJ, Weisenburger DD et al. Autologous stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000; 6: 640–645.

    Article  CAS  Google Scholar 

  13. Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and marrow transplant and autologous blood and marrow transplant registries. Br J Haematol 2003; 120: 793–800.

    Article  Google Scholar 

  14. Decaudin D, Brousse N, Brice P et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3 year follow up study. Bone Marrow Transplant 2000; 25: 251–256.

    Article  CAS  Google Scholar 

  15. Oinonen R, Jantunen E, Itala M et al. Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymph 2002; 43: 1229–1237.

    Article  Google Scholar 

  16. Dreger P, Martin S, Kuse R et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1: 87–94.

    Article  CAS  Google Scholar 

  17. Andersen NS, Pedersen L, Elonen E et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Hematol 2003; 71: 73–80.

    Article  Google Scholar 

  18. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression free survival in mantle cell lymphoma – results of a prospective randomized trial of the European MCL network. Blood 2005; 105: 2677–2684.

    Article  CAS  Google Scholar 

  19. Khouri IF, Romaguera J, Kantarjian H et al. Hyper – CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16: 3803–3809.

    Article  CAS  Google Scholar 

  20. Khouri IF, Saliba RM, Okoroji GJ et al. Long term follow up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. Cancer 2003; 98: 2630–2635.

    Article  Google Scholar 

  21. Hess G, Flohr T, Huber C et al. Safety and feasibility of CHOP/rituximab induction treatment followed by high dose chemoradiotherapy and autologous PBSC transplantation in patients with previously untreated mantle cell or indolent B cell non Hodgkins lymphoma. Bone Marrow Transplant 2003; 31: 775–782.

    Article  CAS  Google Scholar 

  22. Gianni AM, Cortelazzo S, Magni M et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29 (suppl. 1): S10–S13.

    Article  Google Scholar 

  23. Belhadj K, Delfau-Larue MH, Elgnaoui T et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B cell nonHodgkins lymphoma: a single institution study. Ann Oncol 2004; 15: 504–510.

    Article  CAS  Google Scholar 

  24. Freedman AS, Neuberg D, Gribben JG et al. High dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission. J Clin Oncol 1998; 16: 13–18.

    Article  CAS  Google Scholar 

  25. Brugger W, Hirsch J, Grunebach F et al. Rituximab consolidation after high dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective multicenter phase II study. Ann Oncol 2004; 15: 1691–1698.

    Article  CAS  Google Scholar 

  26. Mangel J, Buckstein R, Imrie K et al. Immunotherapy with rituximab following high dose therapy and autologous stem cell transplantation for mantle cell lymphoma. Sem Oncol 2002; 29 (suppl 2): 56–69.

    Article  CAS  Google Scholar 

  27. Mangel J, Leitch HA, Connors JM et al. Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15: 283–290.

    Article  CAS  Google Scholar 

  28. Gopal AK, Rajendran JG, Petersdorf SH et al. High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162.

    Article  CAS  Google Scholar 

  29. Behr TM, Griesinger F, Riggert J et al. High dose myeloablative radioimmunotherapy of mantle cell non Hodgkins Lymphoma with the iodine 131 labeled chimeric anti CD2O antibody C2B8 and autologous stem cell support. Cancer 2002; 94: 1363–1372.

    Article  CAS  Google Scholar 

  30. Sohn SK, Bensinger W, Holmberg L et al. High dose therapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: The Seattle experience (abstract). Proc Am Soc Clin Oncol 1998; 17: 17a.

    Google Scholar 

  31. Mollee P, Lazarus HM, Lipton J . Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2004; 33: 271–277.

    Article  CAS  Google Scholar 

  32. Grigg A, Ritchie D . Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579–590.

    Article  CAS  Google Scholar 

  33. Khouri IF, Lee MS, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293–1299.

    Article  CAS  Google Scholar 

  34. Rifkind J, Mollee P, Messner H, Lipton J . Allogeneic stem cell transplantation for mantle cell lymphoma – does it deserve a better look? Leuk Lymphoma 2005; 46: 217–223.

    Article  Google Scholar 

  35. Armitage JO . Allotransplants for mantle cell lymphoma. Ann Oncol 2002; 13 (Suppl 2): 9a.

    Google Scholar 

  36. Popplewell LL, Nademanee A, Carter N et al. Autologous vs allogeneic cell transplantation for mantle cell lymphoma (MCL): outcomes over a 10-year period at City of Hope (abstract). Blood 2004; 104: 255a.

    Google Scholar 

  37. Grigg A, Bardy P, Byron K et al. Fludarabine-based nonmyeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107–110.

    Article  CAS  Google Scholar 

  38. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407–4412.

    Article  CAS  Google Scholar 

  39. Maris MB, Sandmaier BM, Storer BE et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  Google Scholar 

  40. Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75–80.

    Article  CAS  Google Scholar 

  41. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  Google Scholar 

  42. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and bone marrow transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

  43. Kasamon YL, Jones RJ, Diehl LF et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005; 11: 39–46.

    Article  Google Scholar 

  44. Vandenberghe E, Ruiz de Elvira C, Isaacson P et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)?: a study from the EBMT. Blood 2000; 96: 482a.

    Google Scholar 

  45. Berdeja JG, Jones RJ, Zahurak ML et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001; 7: 561–567.

    Article  CAS  Google Scholar 

  46. Robinson SP, Schmitz N, Taghipour G et al. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease (abstract). Blood 2004; 104: 622a.

    Google Scholar 

  47. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression free survival. J Clin Oncol 2002; 5: 1288–1294.

    Article  Google Scholar 

  48. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol 2005; 23: 1984–1992.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. T L Kiss and P Mollee: Contributed equally to this review.

Authors and Affiliations

  1. Hematology-Oncology, Hopital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada

    T L Kiss

  2. Hematology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

    P Mollee

  3. Comprehensive Cancer Center of Case Western Reserve University Hospitals of Cleveland, Cleveland, OH, USA

    H M Lazarus

  4. Allogeneic Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

    J H Lipton

Authors
  1. T L Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Mollee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J H Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J H Lipton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiss, T., Mollee, P., Lazarus, H. et al. Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplant 36, 655–661 (2005). https://doi.org/10.1038/sj.bmt.1705080

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705080

Keywords

This article is cited by

Search

Advanced search

Quick links